Overview of biomarkers and surrogate endpoints in drug development
about
GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patientsQuantitative biomarker analysis of synovial gene expression by real-time PCRBiomarkers predicting antidepressant treatment response: how can we advance the field?Proteomics and biomarkers in clinical trials for drug developmentMore sound cancer therapy biomarker development with active noise control.Surface enhanced laser desorption ionization spectrometry reveals biomarkers for drug treatment but not dose.Pharmacologic biomarkers in the development of stratified cancer medicine.The immuno-oncology framework: Enabling a new era of cancer therapy.OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.Clinical implications of microRNAs in cancer.The promise and reality of pharmacogenetics in psychiatryA pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.Molecular profiling approaches for identifying novel biomarkers.Systematic review of the concurrent and predictive validity of MRI biomarkers in OABiomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability.Molecular staging individualizing cancer management.Biomarkers in systemic lupus erythematosus.GUCY2C molecular staging personalizes colorectal cancer patient managementBiomarker method validation in anticancer drug developmentThe Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogatThe role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus.Pharmacogenomics: the promise of personalized medicine for CNS disorders.Validation of analytic methods for biomarkers used in drug developmentIndustry perspectives on biomarker qualification.Biomarkers of apoptosis.The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.Searching for 'omic' biomarkersMolecular imaging and targeted therapies.What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema.Assessing the clinical utility of diagnostics used in drug therapy.Applications of 'decisionable' biomarkers in cardiovascular drug development.Bioinformatics advances for clinical biomarker development.Impact of biomarkers on clinical trial risk.microRNAs with different functions and roles in disease development and as potential biomarkers of diabetes: progress and challenges.Dynamic contrast-enhanced MRI for oncology drug development.MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.A proteomic approach for the identification of immunotoxic properties of Tulipalin A.Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic?What evidence do we need for biomarker qualification?
P2860
Q24641833-FD7B1991-87D5-4ECB-AACB-D87D167468D8Q24795033-0460DF02-2591-4FF4-B929-A0062EA89EBCQ27026147-8E0672EC-6386-4D45-B5FF-3D8385D602BFQ30402667-E8F10C1E-23ED-44FB-B11A-6A9197E904A0Q30442454-66D446F6-6C04-4E09-9D13-0909E3334BDDQ33235551-C0CCE49B-D8C9-45F9-8BAC-B867BE1A2A7EQ33626476-43AB4125-D6B3-4825-A675-1057EE01750EQ34284462-F09480E5-541F-469D-9098-DD0164486542Q34475498-FDFF9C78-9229-4B23-BBB3-EB6E323EB815Q34570698-BDEFEC06-B14D-42AA-A403-03E4D7DD25E4Q35226451-A4889FB3-8B7C-4DF3-A6F9-8358AB089A7DQ35681400-C1E29C16-316A-499E-9035-EE1FBC741255Q35684838-537ECC0F-A982-4BB8-89F4-2E03710F8639Q35709531-912CD8CD-0076-4A46-97B2-E38F75C9C438Q35799602-CB7A3399-CA03-4800-B858-48E51567BAFAQ35854173-4B62F680-5190-4892-8FC9-2F2CFEBD690EQ35882067-B9438FC1-24BD-4D92-85EE-89FD01852E9CQ36336227-AA4CB182-B8BB-4A0C-92B9-F5B625D48D19Q36484621-E4217D11-AC9C-4D56-8217-BFC62B57CCEAQ36966415-B0F0B679-4956-4E55-BC4F-BA9C72BC126BQ37035523-95707A45-67B0-4613-B623-D0D90E91B84BQ37272534-BA833EFB-2281-468C-9297-F74DED761A91Q37284255-3FD43C91-6500-45B9-AA1B-3669BA980487Q37341324-36FBC587-72CF-4031-9F4F-C5D5FBC1E875Q37400048-5E1C76D9-C3F3-4F20-A007-D37C11097478Q37418999-0217F895-165A-402B-8805-069F97451AF1Q37462448-B1AC3D80-9EE6-437E-9E3F-50D3EDA2ABC2Q37517240-52530D56-DCCB-445D-9AA2-2A2F6989F1D5Q37732704-BB36A4C1-F3B0-4E66-8CBD-CF6F32FFB773Q37761908-91CFB1E6-873F-4D68-915E-58DA5B400F71Q37803526-86DCCD45-FC48-4193-9FF6-148D3D8BAAF3Q37816414-8E2AFD11-2237-4291-B32A-018C0ADB1421Q38088378-DA951214-406F-4F23-8A63-BDD808C0B7C4Q38148601-25288FAA-E2C5-4374-85EA-05C509158DBFQ38375953-ECC9E37F-9354-40A5-BCD6-4CABDCCBD692Q38725827-916710DD-290A-4F43-94BC-2F2A8837B8BFQ38867829-1C35D544-E671-4635-AC0A-3706A4C9F225Q39336320-44C35834-4C33-4B01-BC48-F0F0DECE2058Q42736759-0326F319-760C-4C22-A61B-8C344DF68890Q47571617-BB44B9F8-623C-4E99-B4FE-30F8E5FAC90A
P2860
Overview of biomarkers and surrogate endpoints in drug development
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Overview of biomarkers and surrogate endpoints in drug development
@ast
Overview of biomarkers and surrogate endpoints in drug development
@en
Overview of biomarkers and surrogate endpoints in drug development
@nl
type
label
Overview of biomarkers and surrogate endpoints in drug development
@ast
Overview of biomarkers and surrogate endpoints in drug development
@en
Overview of biomarkers and surrogate endpoints in drug development
@nl
prefLabel
Overview of biomarkers and surrogate endpoints in drug development
@ast
Overview of biomarkers and surrogate endpoints in drug development
@en
Overview of biomarkers and surrogate endpoints in drug development
@nl
P921
P356
P1433
P1476
Overview of biomarkers and surrogate endpoints in drug development
@en
P2093
John A Wagner
P356
10.1155/2002/929274
P577
2002-01-01T00:00:00Z